Studies on Histamine Metabolism in Mastocytosis  by Granerus, Göran et al.
0022-202X/83/8005-041 0$02.00/0 
TH E JOURNAL 0 F i NVESTIGATIV E D E RM ATOLOGY, 80:4 10-416, 1983 
Copyrighl © 1983 by The Willia ms & Wilkins Co. 
Vol. 80, No.5 
Printed in U.S.A. 
Studies on Histamine Metabolism in Mastocytosis 
G6RAN GRANERUS, M.D., JoN H . 0LAFSSON, M.D., AND GosTA RouPE, M.D. 
Departments of Clinical Physiology (GG) and Dermatology (JHO, GR), Sahlg ren.sha Sjuhhuset, University of Goteborg, Gotebo1g, Sweden 
The urinary excretion of histamine and its main me-
tabolite, 1-methyl-4-imidazoleacetic acid (MelmAA), was 
determined in 30 adult patients with the clinical diag-
nosis of urticaria pigmentosa (UP). Clinical and labora-
tory investigations including skin histology, bone mar-
row examination, and scintigraphy of the skeleton, liver, 
and spleen revealed systemic manifestations in 14 cases. 
Among the 16 cases with dermal proliferation of mast 
cells only 3 cases classified a s telangiectasia macularis 
eruptiva perstans (TMEP). All patients with systemic 
mastocytosis and UP excreted increased amounts of 
MelmAA in the urine while normal amounts were found 
in 2 of the patients with TMEP. A significant correlation 
existed between MelmAA excretion and the extent of 
mast cell infiltration in skin and internal organs. No such 
correlation was found for urinary histamine. Urinary 
MelmAA but not histamine is therefore considered a 
useful indicator of systemic involvement by reflecting 
the size of the mast cell histamine pool. The main symp-
tom of the patients was pruritus, which was moderate to 
severe in 17 and mild or absent in 13 cases. Gastrointes-
tinal symptoms were present in 14 patients. However, 
there was no obvious correlation between the excretion 
of MelmAA and any of the symptoms recorded. Neither 
was the severity of pruritus correlated to the histamine 
content of the skin, which was measured in both lesional 
and unaffected skin in 23 of the patients- Thus, symptoms 
possibly caused by histamine in mastocytosis patients 
are not directly related to urinary histamine metabolite 
excretion or tissue histamine content. 
Urticaria pigmentosa (UP) implies a d erm al proliferation of 
mast cells. Accumulation of mast cells also in organs other than 
the skin, i.e ., bone m arrow, skeleton, liver, spleen, lymph nodes, 
a nd th e gastrointestina l tract, is found in systemic mastocytos is 
(SM) . UP may sh ow symptoms of m ast cell histamine release 
like urtication a nd e pisodic intense pruritus, while in other 
patien ts the disease may be asymptomatic or cause only minor 
complaints . Extensive mast cell infiltratio n may give rise to 
clinical symptoms attributable to gen eral release of histamine 
such as flushing, tachycardia, h ypotens ion, and gastric hyp erse-
cretion. 
The severity a nd extent of m ast cell proliferation has been 
difficult to evaluate. Thus, widespread lesions of UP do not 
indicate dissemination of the disease s ince forms involving 
internal organs w ith ou t skin lesions exist [1]. In a recent study 
by Gr a nerus et al [2) m easurement of t h e major histamine 
metabolite, 1-methyl-4-imidazoleacetic acid (MelmAA) in t h e 
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urine r eliably reflected the mast cell population of t h e skin. In 
the present study, this m etabolic marker has been used to 
evaluate the total m ast cell m ass of the body as indicated b y 
c linical and la boratory findings of mast cell accumulation in the 
s kin, bone marrow, skele ton, liver, spleen , and gastrointestinal 
tract, a nd to correlate the patient's symptoms with the hista-
mine turnover rate. 
PATIENTS AND METHODS 
Patients 
Thirty adult patients, 12 men and 18 women, with known UP were 
included in this study. Their ages ranged from 22 to 78 years, mean 49 
years. In aU cases the disease had its onset in adul thood and t he mean 
dw·ation was ll years with a range of 0.5- 38 yeru·s. T he diagnosis of the 
skin eruption was based on the usual cl inical cri te ria for UP, viz. typical 
multip le reddish-brown maculae urticating after rubbing. The less 
common form of generalized UP, telangiectasia macularis erupt iva 
perstans (TMEP) , was chru·acterized by confluent maculru· areas of 
telangiectasia and erythema. Histologic confirmation of the clinical 
diagnosis was obtained in all patients. Part of this material was included 
in preliminary repor ts [3,4]. 
Each patient estimated the severi ty of pruritus at the time of the 
investigation on a 4-point scale: absence of, mild, moderate, or sever e 
itch. Gastrointestinal symptoms and verified peptic ulcers were also 
recorded. Systemic effects of histamine, like tlush attacks, headache, 
a nd blood pressu1·e fall, were no t recognized in the history of a ny of the 
patients. Pm·tinent clinical and laboratory details of each patient ru·e 
given in Table I; the patients ru·e listed in the order of urinary excretion 
Laboratory I n.uestigation:; 
Determination of the hemoglobin concentration in the blood and 
total and differential white cell counts were performed by standard 
techniques. In the peripheral blood, 0-l% of basophils was considered 
normal. The absolute number of eosinophils was determined, the nor-
mal upper reference value being 300 X lOG / L. 
Bone marrow smears were performed by conventional aspiration 
technique (sternal puncture) and stained with May-G rtinwald-Giemsa 
for morphologic evaluation . The number of mast cells was coun ted 
from at least 2000 nucleated bone marrow cells. Normally no mast cells 
a1·e found . More than 2 mast ce Lls per 1000 coun ted nu cleated cells were 
considered abnormal and indicative of SM [5]. The upper reference 
value was 10% of the myeloid ce lls for eosinophils and 2% for the 
basophils. Bone man ·ow hemosiderin was stained according to Hansen 
a nd Weinfeld [6] and graded according to Lund in et al [7]. Grade I and 
II and sideroblasts 20-50% were accepted as normal. 
For histologic diagnosis and for measurements of histamine content, 
s kin biopsy specimens were obtained from hyperpigmented patches of 
th e trunk and from a1·eas in between, representing lesional a nd unaf-
fected skin respectively. For anesthesia 1% lidocaine without adrenaline 
was injected in the periphery of the ru·ea to be biopsied and a 4-mm 
punch biopsy was procured. For histologic examination the specimens 
were fixed in formalin and embedded in pru·affin and 2- to 3-1-'m thick 
sections were s.tained with Giemsa's reagent. The histamine content 
was measured both in biopsies taken from a pigmented ar ea and in 
s pecimens from a close unaffected pru·t of the skin. Skin from the 
a bdomen of ll hea lthy subjects served as controls. Their skin histamine 
content was 9.3 ± 2.4 11g/g wet weigh t (mean ± SD) , the upper normal 
limit being 14 p.g/ g. 
Scintigraphic examina tions of the liver and spleen were per fo rmed 
by using """'Tc sulfur colloid and gamma camera technique according 
to the method described by Lru·son and Nelp [8]. The largest spleen 
a rea in the lateral or posterior projections is presented in T able I. The 
upper limit of the normal range was 81 em" [9]. For scin t igraphic 
examination of the skeleton """'T c methylene diphosphonate was used 
[10]. Bone scans with one or several distinct foci of rad ionuclide up take 
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TABLE I. Pertinent clinical and labora.tory details of 30 adult patients with mastocytosis 
Patient 
Age Clinical Duration Pruritus at Gastrointestina l 
No Sex (years) diagnosis (years) present mani festatio ns 
1 F GO SM 28 Moderate Diarrhea 
2 M 69 SM 14 No No 
3 M 57 SM 0.5 Moderate No 
4 F 78 SM 4 Severe Duodenal ulce r 
5 F 71 SM 20 Severe No 
6 F 56 SM 15 Severe No 
7 M 53 SM 38 Mild No 
8 M 58 SM 10 Mild No 
9 M 50 SM 12 Moderate Duodenal ulcer 
10 F 58 SM 23 Severe Gastritis, diarrhea 
11 F 38 SM G Severe No 
12 F 36 UP 8 Mild Gastritis 
13 F 66 UP 13 Severe Duodenal ulcer 
14 M 61 SM 4 Moderate Gastri tis 
15 F 52 SM 13 Moderate Gastri tis 
16 M 60 UP 15 Mild Duodenal ulce r 
17 F 26 UP 6 No No 
18 M 30 UP 5 No No 
19 M 70 SM .1 5 No No 
20 F 26 UP lO Mild Duodenal ulcer 
21 F 37 UP 12 Mild No 
22 F 47 UP 6 Moderate No 
23 M 37 UP J] Moderate No 
24 M 30 T MEP 4 Moderate Gastri tis, diarrh ea 
25 M 53 UP 13 Mild No 
26 F 34 UP 4 Moderate Gastri tis 
27 F 22 UP I Moderate Gastritis 
28 F 23 UP 3 Mild No 
29 F 65 TMEP 11 Moderate Duodenal ulce r 
30 F 35 TMEP 17 No No 
as well as t hose with a n increased genera lized uptake were considered 
abnormal. 
Methods for Studies of Histamine Metabolism 
Urine was co llected in 24 -h periods, usually on 2 consecu t ive days . 
To avoid bacterial growth, th e UTine was ac idified with hydrochloric 
acid to a pH of less than 2. During t he days of study t he patients ate a 
stand ru·dized diet with a defined , low histamine conten t [ll]. 
The histamine conten t of skin and mine was dete rmined with t h e 
enzymatic double isotope method described by Beaven et al [12] with 
addition of chromatographic sepru·ation of t he reaction product for th e 
urine specimens [13]. Skin biopsies were homogenized in 0.1 M sodium 
phosphate buffer, pH 7.9, and t he homogenate was frozen overnigh t, 
thawed, and cen t rifuged. 
1-Methyl-4-imidazoleacetic ac id MelmAA was conver ted to t he ethyl 
ester , which was extracted with ether and estimated by t hin- layer 
chromatography according to the method of Granerus a nd Magnusson 
(14], with s ligh t modifications [15]. 
[' 4 C}-Histamin.e Study in Patients Nos . I and 5 
About 10 fig C''C]-his tamine (sp act 31 mCi/ mmol) labeled in th e 
two posit ion of the imidazo le ring was disso lved in 1000 ml saline a nd 
infu sed at a constant rate for 6 h . Urine was collected d uring t h e 
infusion period a nd during t he next 18 h . The urinary excretion of tota l 
'"C-activity and [' ''C)-histamine and its metabolites was determined 
with an ion excha nge clwomatographic method described by Bergmark 
and Granerus [16]. 
['"C)-Histidine S tudy in Patient No. 1 
About 500 fiCi of ['"C)-histidine labeled in t he two position of th e 
imidazole ring (Amersha m, England, sp act 55 mCi/mmol) was dis-
solved in 10 ml saline and injected intravenously on day 1 of the study. 
Urine was co llected fo r 30 days and t he daily excretion of tota l 14C-
activity a nd of [' ''C]-MelmAA was measured with an ion excha nge 
chromatographic method as described by Bergmark a nd Granerus 
(16]. On day 5 a ll quantitatively importa n t metabol ites were measured. 
During days 1, 8, 13, 18, 21, a nd 30 t he patient ate t he standardized diet 
[11] and the urinary excretion of endogeno us histamine and MelmAA 
was measw·ed as well. The administration of [' "C)-histidine was ap-
proved by th e Committee for Isotope Studies at the hospital and the 
patient's informed consen t was obtained. 
Bone Scin tigraphy Skin histamine Urinary excretion 
marrow Bone Liver (mast Spleen Le- Unaf-
cells in- scan en- s ional fected Histamine MelmAA 
abnor- large- area (!'g/ 24 h) (mg/ 24 h) creased) 
mal ment.. 
(em ~ ) (pg/ g) (!tg/ g) 
Yes Yes No 91 134 58 158 48.4 
Yes Yes No 100 104 41.6 
No Yes No 105 202 37 79 41.3 
Yes Yes Yes 49 590 35 66 34 .1 
Yes Yes Yes 128 109 58 11 3 24.1 
Yes No No 48 46 23.0 
Yes Yes No 50 96 15 120 14.1 
Yes Yes No 58 89 37 150 14.1 
Yes Yes No 37 114 31 69 11.2 
Yes Yes No 75 176 53 27 9.5 
Yes No No 50 153 34 42 9.3 
No Yes No 55 136 27 133 8.9 
No Yes No 48 99 16 26 8.5 
Yes Yes No 46 .1 40 49 18 8.4 
Yes No No 40 33 8.4 
No Yes No 35 147 26 43 8.0 
No No 56 44 21 41 7.8 
No No No 80 42 7.6 
Yes No No 66 20 6.6 
No No No 50 112 32 57 6.3 
No No No 71 42 15 149 6.3 
No No No 55 58 20 40 5.7 
No No No 31 161 24 31 5.5 
No No No 53 52 37 62 5.3 
No Yes No 47 25 28 20 5. 1 
No No No 38 22 5.0 
No No No 40 52 21 31 4.8 
No No No 70 92 13 110 4.5 
No Yes No 59 44 64 19 3.3 
No 12 3.0 
RESULTS 
Clinical and Laborat01y Examinations 
Table I summarizes essential clinical and laboratory details 
of 30 patients with mastocytosis with onset in adul thood. The 
clinical diagnosis of SM was based on direct demonstration of 
an increased number of mast cells in an internal organ (the 
bone maJTOW examination) , or indirect evidence of abnormali-
ties in at. least 2 internal organs (the scintigraphic examinations 
of the skeleton, liver, and spleen) . According to this definition, 
the material comprised 14 cases of SM, 13 cases of UP, and 3 
cases of TMEP. In fact there were 19 patients who had abnor-
malities in an organ oth er than the skin, and the skeleton was 
found to be the most common location (15 patients). Thirteen 
patients had one or several locations of distinct focal uptake in 
the skeleton, while 2 patients (Nos. 1 and 8) presented a 
generalized and symmetrical uptake of the radionuclide. Thir-
teen patients had increased numbers of mast cells in th e bone 
marrow. Two were found to have an enlarged liver. Splenomeg-
aly was found in 4 patients, while a focally reduced uptake of 
the radionuclide was detected in the spleen of 1 patient (No.4). 
Seven patients had symptoms of gastritis and 6 had duodenal 
ulcer demonstrated by x-ray. Three patients complained of 
diarrhea and 1 of these (No. 1) had a severe malabsorption 
syndrome. 
All patients had normal hemoglobin values in the peripheral 
blood (normal range 132-166 g/L for males and 116-149 g/L 
for females) except 1 patient who showed slight anemia (No. 
28). Total white cell -counts we1·e normal in all but 4 patients 
(Nos. 1, 3, 5, and 24). Patients 1 and 5 had slight leukopenia 
while patients 3 and 24 ha d leukocytosis. Patient 3 rapidly 
developed a histologic p icture in the crista biopsy consistent 
with a myelofibrosis. Nine patients (Nos. 1, 2, 3, 4, 9, 10, 12, 25, 
and 26) had increased numbers of eosinophils in the peripheral 
blood as measmed by absolute eosinophil count, and 2 of these 
9 patients (Nos. 2 and 10) had eosinophilia and increased 
numbers of mast cells in the bone marrow. T he number of 
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basophils in the peripheral blood was normal in all patients bu t 
one (No.4, 2%). 
A morphologic examination of bone marrow smears was 
performed in all patients. In general th ere was a good cellularity. 
T he number of mast cells varied fTom 0- 20 cells per 1000 
nucleated bone marrow cells: 0-2 in 17 cases and around 10 per 
1000 in the oth er 13 patients. T he num ber of eosinophil myeloid 
cells was increased in 9 cases and at the upper borderline (8-
9%) in another 6 cases. T he percentage of basophil cells was 
not elevated in t he marrow. Bone marrow hemosiderin was 
lacking or only trace in 7 cases (of which five were female) and 
a decreased percentage of sideroblasts was noted in 8 cases. 
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FIG l. Urinary excretion of endogenous histamine metabolite Me-
ImAA (mg/24 h) in 30 adult mastocytosis patients grouped according 
to cl inical diagnosis (TMEP = te langiectasia macularis eruptiva per-
stans, UP = urticaria pigmentosa, SM = systemic mastocytosis). T he 
upper normal limit (4.1 mg/24 h) and median value in each group are 
indicated. 
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FIG 2. Urinary excretion of endogenous MelmAA (mg/24 h) in 30 
adul t mastocytosis patients grouped according to spread of mast cell 
infil tration. T he upper normal limit (4.1 mg/24 h) and median value in 
each group are indicated. 
Endogenous Histamine Metabolism 
The ur inary excretion of histamine was normal (< 40 J.Lg/24 
h ) in 11 patients (37%) and increased in the other 19 (Table 1). 
It was normal in 4 patients with SM (29%) and increased in 9 
patients (56%) with involvement of the skin only. Thus, hista-
mjne excretion in the urine was a poor indicator of the presence 
and the extent of mast cell disease in these patients . 
The major histamine metaboli te MelmAA was increased (> 
4.1 mg/24 h) in all but 2 patients. All patients with UP and 
T MEP excreted less than 9.0 mg/24 h, while 11 of the 14 
patients (79%) with SM excreted more than 9.0 mg per day (Fig 
1). It is clear fro m Fig 2 that the more widespread the infil tration 
of mast cells, the higher was the excretion of M elmAA. 
Five patients had no pruri tus while 8 had mild, 11 moderate, 
and 6 severe pruritus (Table I) . All 6 patients with severe 
prur itus excreted more than 8 mg MelmAA per day bu t other-
wise there was no obvious correlation between the severi ty of 
pr ur itus and histamine metaboli te excretion. Five of the pa-
tients with severe pruritus also had SM , which explains why 
severe pr w·itus might indicate systemization of the disease. 
Three of these 6 pa tients felt better after exposure to the sun 
and in the other 3 common ant ihistamines (H,-antagonists) 
reduced the itching. 
The histamine content in the skin could be measured in most 
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of the patients (Table 1). It was above tHe upper normal limit 
in all cases except 1 but did not seem to be related to the 
severity of pruritus, either !n lesional _or in u_naffec~ed skin. o_n 
the other hand, patients w1th systemic mamfestatwns of theu 
disease had significantly higher skin histamine values than UP 
patients, both in lesional (p < 0.05) . and _in unaffected ~kin 
biopsies (p < 0.001) (Fig 3). As the h1stam~ne content mam_Jy 
reflects the number of mast cells, an extens1ve mast cell prolif-
eration in the skin seems to indicate a tendency toward accu-
mulation of mast cells in other organs also. 
There was no indication of an increased histamine tmnover 
in patients with symptoms from the gast~·ointe~tinal tract and 
no obvious difference between the mamfestatwns evaluated. 
However the dominating clinical featme in patient No. 1, with 
the high~st MelmAA excretion, h ere classified as di~-rh~~· was 
a malabsorption syndTome with steatorrhea and ·~ability t_o 
absorb electrolytes, especially calcium and magnesmm. Th1s 
patient probably has a huge mast cell mass in the muco~a. of 
the gut causing the very high histamine turnover and explammg 
these symptoms. 
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FIG 3. Skin histamine contenL (ftg/ g) in 23 adul t mastocytosis pa-
tients grouped according to clinical diagnosis (TMEP = te langiectasia 
macularis eruptiva perstans, UP = urticaria pigmentosa and SM = 
systemic mastocytosis). The upper normal limit (14 ~tg/g ) and med ian 
values are indicated. 
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f 4 C}-Histamine Study in Patients Nos. 1 and 5 
To study the fate of histamine released into the bloodstream, 
2 of the patients with SM were given a slow intravenous infusion 
of '"C-labeled histamine duTing 6 h , and the urinary excretion 
of radioactive histamine and its metabolites was measuTed. The 
results are shown in Table II. It is evident that the metabolic 
pattern is the same as in th e controls. During the infusion 
period the quotient between the main metabolite, MelmAA, 
and unchanged [' ''C)-histamine in the mine was 4.6 and 10, 
respectively, which is not different from what is found in 
healthy subjects and in sharp contrast to the much higher 
quotient between endogenous M elmAA and free histamine in 
these patients, usually around 200 (molar ratio calculated from 
Table 1) . During the following 18 h of urine collection the •·•c 
quotient increased to 5.4 and 27, respectively, still faT from the 
endogenous value. 
The 2 patients excreted 78-91% of the given dose in 24 h, 
which is within the normal range and indicates no uptake or 
exchange between exogenous and endogenous histamine in the 
body of these mastocytosis patients. It was not possible to 
account for ail radioactivity in the urine in terms of known 
histamine metabolites. N-acetylhistamine was not detected. 
['" C)-Histidine Study in Patient No. 1 
A chTomatographic analysis of the [' "C)-histidine used for 
injection showed that the solution contained 88% [' 4C]-histidine 
and 2.6% [' ''C)-histamine. On the first day of study, 21% of the 
injected amount of '"C-activity was excreted in the urine. Dm-
ing the following 29 days only small amounts of radioactivi ty 
appeared in the urine (Fig 4) . Al together , 25% of given '''C-
activity was excreted in 30 days. 
From day 4 onward the excretion of total 14C-activity paTal-
lelled the excretion of the major histamine metabolite, ( 14 C]-
M elmAA, which accounted for 25-35% of the daily •·•c activity 
found in the urine. Both total ' ''C and [' "C]-MelmAA declined 
monoexponentially with time. The equations of these curves 
were y = 0.215 X e- o.o.J!Jx and y= 0.059 X e- 0.0'' 3\ where x is t he 
day of study and y the percent of total •·•c and [' ''C]-MelmAA 
respectively in the urine. The coefficient of deterrnination (r 2 ) 
was 0.85 and 0.81 (data pair day 26 deleted due to incomplete 
urine collection). 
The latter equation allows calculation of the mean tra nsit 
t ime of the (' ''C]-MelmAA formed in this patient (= 23 days) 
and the total area under the cmve (1.4%). The other known 
metabolites of histamine were measm ed on day 5 and it will be 
seen from Table III that MeimAA accounted for 61% of the 
sum of radioactive histamine m etabolites in th e mi11e that day. 
['"C)-Histamine and methylhistamine were not measmable 
(less than 1%). Assuming that the urinary excretion of [ '"C} 
M elmAA represented a constant fraction of all [ 14 C]-histamine 
catabolized in the body each day and that released ( '''C)-h ista-
mine was rapidly degraded and excreted, the total conversion 
of [' "C)-histidine to histamine was 2.2% in this patient. 
DISCUSSION 
Histaminuria in mastocytosis or UP was first demonstrated 
by Brogren et a! [17] and Demis et a! [18]. Demis [19] has 
experimentally verified that the histaminuria r esults from sim-
ple overproduction of histamine by the increased number of 
mast cells characteristic of mastocytosis, because increased rate 
of histamine synthesis or a block in the catabolism of histamine 
could be excluded as being r esponsible for the histaminuria. 
Demis's basic studies have been extended and the resul ts con-
firmed in this work. 
There are several reports on isolated cases of SM which 
demonstrate increased urinary excretion of free histamine 
(20]. Horiik6va et al [21] measured histamine in the urine of 14 
patients wi th mastocytosis by a radioenzymatic assay and found 
that patients with SM had higher excretion values (> 150 }lg/ 
24 h) tha n those wi th cutaneous mastocytosis (39-88 }lg/ 24 h). 
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TABLE II. Urinary excretion. of mdioactive histamine and metabolites (% of excreted radioactivity in. each period) and total '''C.activity (% 
of infused dose) in 2 patients with systemic mastocytosis 
Palient Period Hi HiOH Me Hi (h) 
0-6 8 8 7 
7-24 8 1 1 
5 0-6 4 2 4 
7-24 2 2 2 
Contro ls I 0-12 7 5 7 
Controls II 0-12 1-6 5-12 
Me lmAA lmAA Conj lmAA 
37 12 3 
43 11 18 
40 16 7 
53 6 17 
43 11 23 
35-60 sum 11-29 
S um 
75 
82 
70 
82 
97 
83-97 
Tota l' ''C 
57 
34 
31 
47 
69 
60-100 
[' ''C)-Histamine was given intravenously during 0-6 hand UJ·ine was collected during 0-6 hand the following 18 h. 
Abbreviations: Hi = histamine, HiOH = histaminol, MeHi = N '-methylhistamine, MeimAA = methylimidazoleacetic acid, ImAA 
imidazoleacetic acid. 
Controls: I= chromatographic method [16], II= isotope dilution method [37,38]. 
Total 14 C 
14C - Me lmAA 
10 20 30 Days 
FIG 4. Urinary excretion of total "C-activity and ["C]-MelmAA in 
patient No. 1. The vertical axis indicates the percentage of injected 14C 
activity eliminated per day (log scale). The horizontal axis shows the 
number of days after administration of L-["C]-histidine. The straight 
lines represent the exponential curve fit (see text) . 
TABLE III. Urinary excretion of radioactive histamine and its 
metabolites on day 5 after ["'C]·h istidine administration in patient 
No. 1 with SM (expressed as % of excreted radioactivity on. day 5), 
and endogenous histamine and M elmAA (NJ/24 h) on. days 1, 8, 13, 
18, 21, and 30 
Day Hi M e Hi MelmAA ImAA Conj !rnA A 
5 < 1 < 1 22 4 10 
1 460 42,800 
8 143 25,700 
13 207 29,900 
18 480 33,200 
21 510 26,100 
30 430 25,200 
Abbreviations as in Table II. 
They sugggested that urinary histamine might be an index of 
the severity of the disease. In our survey of 30 patients, where 
the majority of the clinical and laboratory investigations were 
performed at the same hospital and all patients ate a standard-
ized diet during the day of urine collection, histaminuria was 
not a mandatory finding in mastocytosis, either in the systemic 
form or in the cutaneous form of UP. Furthermore, a low 
urinary histamine excretion did not exclude systemic manifes-
tations in cases clinically diagnosed as UP. This is probably due 
to a very efficient catabolism of histamine in the tissues in these 
patients and calls for a nalysis of urinary histamine metabolites 
as well. 
Reports on urinary excretion of histamine metabolites in 
mastocytosis are scarce. Hansson [22] was able to detect imi-
dazoleacetic acid, which is a metabolite of both histamine and 
histidine, in the urine of 2 patients with UP but not in 2 
controls. Increased amounts of the main histamine metabolite 
MeimAA in the w·ine have been reported in only a few cases 
[23-25]. The essential finding in this study was the striking 
correspondence between the amount of MelmAA excreted in 
the urine and the clinical signs of mast cell proliferation. Only 
a slight increase of MeimAA could be detected in the urine in 
UP, while a significant increment of the metabolite was found 
in generalized mastocytosis, its level depending oh the degree 
of generalization. Interestingly, urinary MeimAA seemed to 
correlate primarily with the extent of mast cell proliferation 
and not with symptoms suggesting histamine release. 
To explain why UP patients have such a small increase in 
MelmAA excretion in spite of having many times the normal 
amount of mast cells in the skin, the turnover rate of histamine 
in the skin mast cells must be assumed to be rather slow. In 
accordance with this assumption, we have recently reported 
that there was only a slight decrease of the MeimAA excretion 
in 3 mastocytosis patients after treatment with PUV A, which 
therapy normalized the number of mast cells in the skin without 
affecting mast cells in other organs [2]. The ['"C)-histidine 
study now performed in patient No. 1 provided a unique op-
portunity to determine the turnover time of histamine in a 
patient with extensive mast cell infiltration in the skin and 
several internal organs. As can be seen in Table I this patient 
had had her skin disease for almost 30 years. Twenty-four years 
before the present admission skeletal x-rays and bone manow 
aspirate smears were found to be noJ·mal, while at the present 
investigation the marrow aspirate showed an increased number 
of mast cells and increased uptake of isotope in the skeleton on 
scintigraphic examination. Fw·thermore, about 5 years before 
the present admission disabling diarrhea with steatorrhea led 
to severe disturbances of serum electrolytes with hypokalemia, 
hypocalcemia, and hypomagnesemia. 
Assuming that the mast cells rapidly and uniformly took up 
['"C)-histidine for decarboxylation to histamine, the finding 
that the [''1C}MelmAA excretion in this patient declined mon-
oexponentially with time makes it possible to calculate the 
mean transit time of histamine in the labeled histamine pool 
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from the rate constant of the equation given in F ig 4. It was 
found to be 23 days, which is in close agreement with what is 
found in similar experiments in the rat [26]. It seems likely, 
therefore, th at the histamine turnovei· rate of the total mast 
cell population in mastocytosis is typically slow, and a high 
urinary output of histamine metabolites is an indication of a 
much enlarged mast cell histamine pool in the body. 
Histamine formatio n from histidine in humans in vivo has 
earlier been demonstrated in 1 healthy subject and 2 patients 
with chronic myelocytic leukemia by m easming radioactive 
histamine metabolites in the urine after an intravenous injec-
tion of L-[' ''C]-histidine [27]. The fTact ion of injected [' ''C)-
histidine appearing as '''C-labeled MelmAA in the mine dw·ing 
14 days was about 0.05% in the normal subject and 0.8% in t he 
leukemic patients. These figures closely corresponded to a 10-
20 times larger excretion ofnonlabeled MelmAA in the patients. 
The mastocytosis patient in this study excreted 0. 7% of the 
injected [' ''C)-histidine as '"C-labeled MelmAA in 30 days and 
about 10 times the normal amount of endogenous M elmAA. 
Thus, the results are comparable in chronic myelocytic leuke-
mia and mastocytosis, the increased histamine formation and 
the increased excretion of MelmAA probably being due to th e 
greatly enlarged populations of basophil leukocytes and mast 
cells, respectively. A similar high ul'inary excretion of MelmAA 
has been observed in only one other neoplastic disorder, viz. in 
1 case of gastric carcinoidosis (28]. 
The diagnosis of SM was based on an abnOl'mal number of 
mast cells in the bone marrow, a pathologic uptake of label into 
the skeleton, and/ or hepatosplenomegaly (Table I) . Objections 
can of comse be raised against the validity of these criteria. The 
scintigraphic examinations used give only indirect evidence of 
mast cell infiltration, but for ethical r easons additional proof of 
the presence of mast cells in organs other than the skin and 
bone marrow was not possible to obtain. Moreover, it is known 
that increased numbers of mast cells occur in th e bone marrow 
secondary to clinical conditions in which the bone marrow is 
damaged, including myxoedema a nd uremia [29]. However, the 
numbers are seldom as high as in SM, and other diseases 
causing mast cell proliferation were not recorded in our patients. 
There are also other organs that were not examined that a1·e 
known to show mast cell proliferation in mastocytosis, for 
instance the gastrointestinal canal, lymph nodes, and the nerv-
ous system. 
As many as 14 of t he 30 investigated patients were found to 
have a systemic disease. This is a high incidence compared with 
the impression ofSagher and Even-Paz [20] of systemic involve-
ment in about 10% of all patients with mastocytosis. The 
difference may be explained by the criteria used for diagnosis 
of SM and possibly also by small patient samples in earlier 
studies. The bone scan appeared to be t he most efficient single 
examination for disclosing systematization. Bone involvement 
as judged from x-ray has been shown most often to occw· in the 
skull, ribs, vertebrae, long bones, and pelvis a nd presents as 
diffuse or circumscribed a1·eas of osteoporosis and/ or osteoscle-
rosis [17,20]. Only the diffuse type of radiographic skeletal 
change has been studied by autopsy or biopsy and shown to 
indicate mast cell proliferation. The incidence of bone involve-
ment in adul t mastocytosis has been found to be 10-40% 
[5,20,30]. The higher incidence of scintigraphic abnormalities 
in the skeleton in this study (50%) may indicate false resul ts in 
some cases. 
The most fi·equent symptom in our patients was pruritus. 
S omewhat unexpectedly, there was no correlation between the 
severity of pruritus and urinary histamine metabolite excretion 
or the histamine content of the skin. Severe prmitus was found 
in patients with very high as well as only moderate increase in 
urinary M elmAA, which means that a few extra milligrams of 
histamine released per day might be responsible for eliciting a 
severe symptom. On the other hand, there was at least 1 patient 
(No. 2) with a very high histamine tumover who did not have 
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any symptoms at all . Thus, large amounts of histamine may be 
liberated in mastocytosis without doing any harm. The Me-
ImAA excretion naturally reflects histamine t urnover in the 
whole population of mast cells in the body, together with other 
types of potential histamine-forming cells, and t he fraction of 
MeimAA originating in an organ causing a certain symptom 
could be comparatively small and easily swamped. Likewise t he 
poor correlation between the severity of prw·itus and the skin 
histamine content suggests that histamine stored in the skin 
does not cause any symptoms. If histamine is responsible for 
.the pruritus in UP the presence of t ills symptom probably 
depends on a critical tissue concentration of released free his-
tamine and not on the content of bound histamin e in the mast 
cell population. Individual differences in sensit ivity to histamin e 
in the skin may also be of importance. 
Gastric hypersecretion is often recognized in the literature as 
a symptom of SM. In that case, this symptom presumably 
means an unusually rapid tw·nover rate of histamine, causing 
spillover of free rustamine into the blood and typical histamine 
effects like gastric hypersecretion, flush, headache, tachycardia, 
and blood pressul'e fall. Several case reports strongly suggest 
that plasma histamine levels can be increased for shorter or 
even longer periods, causing systemic effects; however, in our 
opinion these cases are exceptions to the rule [19,31-34]. The 
[' ''C)-histamine infusion experiments in 2 of the patients with 
SM and high histamine tumover showed a normal catabolism 
of histamine entering the bloodstream. Hence, there was no 
evidence that mastocytosis patients were metabolically pro-
tected against high plasma histamine levels. 
In our experience, adult-onset UP usually remains static. 
However, 3 of our patients with UP developed SM during the 
observation period. The progression of the disease was reflected 
by the increment of the urinary histamine metaboli te. In case 
No.4 a typical eruption ofTMEP was successively replaced by 
the brownish maculae of UP and signs of systemic involvement 
(Table I) . All our patients except 1 (No. 3) have shown a 
favaorable prognosis. This patient developed a myelofibrosi 6 
months after the skin eruption started, which of course might 
be a coincidence rather than a causali ty. High urinary excretion 
of MelmAA (41.3 mg/24 h) before the white cell count rise 
indicated SM, while still higher MeimAA values later on (81.2 
mg/24 h) could be explained by concomitant myeloproliferative 
disease [35]. Recently 2 cases of SM and atypical myeloproli-
ferative disorders have been reported [36]. 
T he authors especially appreciate the help of Dr Bil·1,>i tta Swolin, 
Department of Clinical Chemistry, fo r examining the bone marrow 
smears, and the assistance of Dr Sture Lindberg, Section of Nuclear 
Medicine, for the liver, spleen, and bone scan interpretations. Skill fu l 
technical assistance was given by Ulla B lomgren and Lena Persson. 
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Effect of Varying Dose of UV Radiation on Mammalian Skin: Simulation 
of Decreasing Stratospheric Ozone 
ISAAC WILLIS, M.D. AND JULIAN M. MENTER, PH.D. 
Dermatology R esearch Unit, Department of M edicine, Morehouse School of M edicine, Atlanta, Georgia, U.S.A. 
To better understand the dependence of the incidence 
of squamous cell carcinoma on changes in solar spectral 
distribution and dose regimen, we exposed SK-1 hairless 
mice to solar-simulating radiation (290-400 nm). Select-
ive UV filtration was accomplished by passing this ra-
diation through Schott WG-320 cutoff filters of 0, 0.5, 1.0, 
2.0, and 3.0 mm thickness. Minimal erythema doses 
(MED) were determined for each filter combination. 
Starting with 0.5 and with 0.9 MED, groups of 20 mice 
were irradiated 5 days per week; this was increased by 
20% increments (of the original dose) every 6th day for 
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40 days ("0.5 MED" and "0.9 MED" experimental groups, 
respectively). Other groups of mice were irradiated with 
the same incremental increases, starting at 6.5 J/cm2 
("equal dose" regimen). The salient results were: (1) 
shorter wavelength components appear to preferentially 
produce tumors; (2) resultant observable dose-response 
behavior for each regimen is a complicated function of 
concurrent "light" and "dark" reactions; (3) time-dose 
reciprocity is absent; and (4) there are no straightfor-
ward relationships among tumor efficiency, dose frac-
tionation, and spectral distribution of excitation radia-
Georgia 30310. 
Abbreviations: 
MED: minimal erythema dose 
SCC: squamous cell carcinoma 
UVA: long-wavelength ultraviolet radiation (320-400 nm) 
UVB: middle-wavelength ultraviolet radiation (290-320 nm) 
